Among them, compounds 1–4 exhibited inhibitory activity against PTP1B but no cytotoxicity against the tested five tumor cell lines, suggesting that it has great potential to obtain new PTP1B inhibitors with medicinal use through appropriate structural modifications of these compounds. This evidence concerns the gene PTPN1 and neoplasm.